RO.CH

256.8

-0.31%↓

NOVN.CH

96.19

+0.14%↑

BANB.CH

67.3

+0.67%↑

RO.CH

256.8

-0.31%↓

NOVN.CH

96.19

+0.14%↑

BANB.CH

67.3

+0.67%↑

RO.CH

256.8

-0.31%↓

NOVN.CH

96.19

+0.14%↑

BANB.CH

67.3

+0.67%↑

RO.CH

256.8

-0.31%↓

NOVN.CH

96.19

+0.14%↑

BANB.CH

67.3

+0.67%↑

RO.CH

256.8

-0.31%↓

NOVN.CH

96.19

+0.14%↑

BANB.CH

67.3

+0.67%↑

Search

Lonza Group AG

Atvērts

SektorsVeselības aprūpe

542.4 0.04

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

539

Max

545

Galvenie mērījumi

By Trading Economics

Ienākumi

119M

426M

Pārdošana

59M

3.6B

P/E

Sektora vidējais

54.647

34.393

EPS

4.31

Dividenžu ienesīgums

0.7

Peļņas marža

11.913

Darbinieki

19,299

EBITDA

764M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+23.54% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.70%

2.54%

Nākamie ieņēmumi

2025. g. 23. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3.2B

40B

Iepriekšējā atvēršanas cena

542.36

Iepriekšējā slēgšanas cena

542.4

Ziņu noskaņojums

By Acuity

15%

85%

19 / 374 Rangs Healthcare

Lonza Group AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. jūl. 08:30 UTC

Peļņas
Galvenie tirgus virzītāji

Lonza Shares Rise After Outlook Lift for Core Business

2025. g. 9. maijs 05:18 UTC

Peļņas

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

2025. g. 18. febr. 12:22 UTC

Iegādes, apvienošanās, pārņemšana

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

2025. g. 23. jūl. 08:00 UTC

Tirgus saruna
Peļņas

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

2025. g. 23. jūl. 04:44 UTC

Peļņas

Lonza 1H Sales Grew 19% at Constant Currency

2025. g. 23. jūl. 04:43 UTC

Peļņas

Lonza 1H Core Ebitda Margin 29.6%

2025. g. 23. jūl. 04:43 UTC

Peļņas

Lonza: Margins Will Be Only Minimally Affected

2025. g. 23. jūl. 04:42 UTC

Peļņas

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

2025. g. 23. jūl. 04:42 UTC

Peļņas

Lonza: This Is Mainly From Weakening of U.S. Dollar

2025. g. 23. jūl. 04:38 UTC

Peļņas

Lonza 1H Net Pft CHF426M

2025. g. 23. jūl. 04:37 UTC

Peļņas

Lonza Backs 2025 View for CHI Business

2025. g. 23. jūl. 04:36 UTC

Peļņas

Lonza Had Seen CDMO Business Core Ebitda Margin Approaching 30% in 2025

2025. g. 23. jūl. 04:36 UTC

Peļņas

Lonza Sees CDMO Business Core Ebitda Margin of 30%-31% in 2025

2025. g. 23. jūl. 04:35 UTC

Peļņas

Lonza Had Expected 2025 CDMO Business Sales Growth at Constant Currency of About 20%

2025. g. 23. jūl. 04:35 UTC

Peļņas

Lonza Expects 2025 CDMO Business Sales Growth at Constant Currency of 20%-21%

2025. g. 23. jūl. 04:33 UTC

Peļņas

Lonza Upgrades 2025 Full-Year CDMO Sales and Margin Outlook

2025. g. 23. jūl. 04:32 UTC

Peļņas

Lonza 1H EBITDA CHF1.01B

2025. g. 23. jūl. 04:32 UTC

Peļņas

Lonza 1H Core Ebitda CHF1.06B

2025. g. 23. jūl. 04:32 UTC

Peļņas

Analysts Saw Lonza 1H Sales at CHF3.51B

2025. g. 23. jūl. 04:32 UTC

Peļņas

Analysts Saw Lonza 1H Core Ebitda at CHF1.00B

2025. g. 23. jūl. 04:31 UTC

Peļņas

Lonza 1H Sales CHF3.58B

2025. g. 23. jūl. 04:31 UTC

Peļņas

Lonza Backs 2025 View

2025. g. 25. jūn. 05:27 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Lonza Group Looks Well-placed to Benefit From U.S. Pharma Trade Policy -- Market Talk

2025. g. 28. maijs 05:38 UTC

Tirgus saruna

Lonza Looks Like Tariff Winner -- Market Talk

2025. g. 9. maijs 14:45 UTC

Tirgus saruna

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

2025. g. 9. maijs 14:42 UTC

Tirgus saruna

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

2025. g. 8. apr. 07:34 UTC

Tirgus saruna

Lonza Well Protected From Tariffs -- Market Talk

2025. g. 29. janv. 08:11 UTC

Tirgus saruna
Peļņas

Lonza's Outlook Looks Positive -- Market Talk

2025. g. 29. janv. 07:22 UTC

Tirgus saruna
Peļņas

Lonza Had a Mixed Year Across Divisions -- Market Talk

2025. g. 29. janv. 07:11 UTC

Tirgus saruna
Peļņas

Lonza's Results Don't Contain Any Surprises -- Market Talk

Salīdzinājums

Cenas izmaiņa

Lonza Group AG Prognoze

Cenas mērķis

By TipRanks

23.54% augšup

Prognoze 12 mēnešiem

Vidējais 668.6 CHF  23.54%

Augstākais 753 CHF

Zemākais 603 CHF

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lonza Group AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

8

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

19 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.